AbbVie Completes Acquisition of Aliada Therapeutics
NORTH CHICAGO, Ill., Dec. 11, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Aliada Therapeutics. With the completion of the acquisition, Aliada is now a part of AbbVie. Aliada’s lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in development for the treatment of patients with Alzheimer’s disease and is currently in a Phase 1 clinical … Continue reading AbbVie Completes Acquisition of Aliada Therapeutics